Clinical trials: Prostate Cancer, Castration Resistant
Metastatic Castration-resistant Prostate Cancer (CRPCa)
Impact of New Generation Hormono-therapy on Cognitive Functions in Elderly Patients Treated for a Metastatic Prostate Cancer
This study will assess the impact of the novel oral hormonal agents (abiraterone acetate or enzalutamide) among elderly metastatic prostate cancer patients.
- Trial name
- COG-PRO (NCT02907372)
- Testing
- neuropsychologic evaluation, oncogeriatric evaluation
- Where
- 6 sites in France
- Volunteers
- 163 people, healthy volunteers welcome
- Sponsor
- Centre Francois Baclesse
Metastatic Castration Resistant Prostate Cancer
A Study Evaluating HC-1119 Single-Dose Pharmacokinetics and Effect of Food on Its Pharmacokinetics
This is a phase I study evaluating HC-1119 single-dose pharmacokinetics and effect of food on its pharmacokinetics in healthy Chinese adults.
- Trial name
- NCT03776968
- Testing
- HC1119
- Where
- China
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- Hinova Pharmaceuticals Inc.
Castration-resistant Prostate Cancer
Liquid Biopsy-based Detection of Resistance to Targeted Therapy in Prostate Cancer Patients
This study will prospectively compare liquid-biopsy based methods for prediction of resistance under androgen-receptor signaling inhibitors.
- Trial name
- PEARL (NCT03601143)
- Testing
- Blood samples prior to a new line of AR-targeted therapy
- Where
- Germany
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Technical University of Munich
Prostate Cancer, mCRPC
A Phase 1/2 Clinical Trial to Evaluate the Safety, Tolerability, Dosimetry, and Anti-tumor Activity of Ga-68-NGUL / Lu-177-DGUL in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) Refractory to Standard Therapy
This clinical trial is an open-label, single-arm, multi-center, escalation (Phase 1 Part B only), rater-blind (Phase 2 only), phase 1/2 trial to evaluate the diagnostic validity/safety of Ga-68-NGUL and efficacy/safety of…
- Trial name
- NCT05547061
- Testing
- Lu-177-DGUL, Ga-68-NGUL
- Where
- 4 sites in South Korea
- Volunteers
- 91 people, healthy volunteers welcome
- Sponsor
- Cellbion Co., Ltd.
Prostate Cancer
Randomized Phase II Trial of Targeted Radiation With no Castration for Mcrpc
This trial tests if the combination of comprehensive metastasis directed therapy delivered by a precision form of external beam radiotherapy (stereotactic ablative radiotherapy), combined with PSMA targeted radiopharmaceutical…
- Trial name
- NCT06084338
- Testing
- stereotactic ablative radiotherapy, Pluvicto, topical testosterone
- Where
- 4 sites in United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development
Metastatic Castration-resistant Prostate Cancer
177Lu-EB-PSMA617 in Patients With Metastatic Castration-resistant Prostate Cancer
This is an open-label, non-controlled, non-randomized study to assess the safety and measure image-based absorbed dose of 177Lu-EB-PSMA-617 in patients with metastatic castration-resistant prostate cancer (mCRPC) who will undergo…
- Trial name
- NCT03403595
- Testing
- 177Lu-EB-PSMA-617
- Where
- China
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Peking Union Medical College Hospital
Metastatic Castration-resistant Prostate Cancer
Phase 1 Study of ATRS-2002 in Healthy Male Adults
To access the safety, tolerability, pharmacokinetics and pharmacodynamics of subcutaneously administered ATRA-2002 against commercially available oral formulation of abiraterone acetate in healthy male adults
- Trial name
- NCT04879589
- Testing
- Abiraterone Acetate
- Volunteers
- healthy volunteers welcome
- Sponsor
- Syneos Health
Prostate Adenocarcinoma, Metastatic Prostate Adenocarcinoma
Bipolar Androgen Therapy (BAT) and Radium-223 (RAD) in Metastatic Castration-resistant Prostate Cancer (mCRPC)
This is a single-arm, multicenter open label, international, phase II study of Bipolar Androgen Therapy (BAT) plus Radium-223 (RAD) in men with metastatic castration-resistant prostate cancer (mCRPC).
- Conditions
- Prostate Adenocarcinoma, Metastatic Prostate Adenocarcinoma, Castration-resistant
- Trial name
- BAT-RAD (NCT04704505)
- Testing
- radium-223, Bipolar Androgen Therapy (BAT)
- Where
- 2 sites in United States, Brazil
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Healthy Subjects, Castration Resistant Prostate Cancer (CRPC)
A Study to Compare Capsule and Tablet Forms of MDV3100 (Enzalutamide) After Administration of a Single Set Dose Under Fasted Conditions in Healthy Male Subjects
A study to evaluate the bioavailability (BA) of a single oral dose of MDV3100 (enzalutamide) formulated as a solid spray dried tablet compared to oral liquid-filled capsules, and the safety and tolerability of oral formulations.
- Conditions
- Healthy Subjects, Castration Resistant Prostate Cancer (CRPC), Relative Bioavailability, MDV3100
- Trial name
- NCT01911741
- Testing
- MDV3100
- Where
- Germany
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- Astellas Pharma Europe B.V.
Metastatic Castration Resistant Prostate Cancer
Abiraterone Acetate in Combination With Tildrakizumab
The purpose of this study is to find out the side effects and safety of a combination of the anti-IL23 targeting monoclonal antibody tildrakizumab in combination with abiraterone acetate in men with metastatic castration…
- Trial name
- ACTIon (NCT04458311)
- Testing
- Abiraterone Acetate, Tildrakizumab
- Where
- 6 sites in Switzerland, United Kingdom
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- Institute of Cancer Research, United Kingdom